Group 1 - Mylan made a $29 billion unsolicited bid to acquire Perrigo in 2015, which was later increased to $34 billion [1] - Perrigo, under then-CEO Joseph Papa, rejected the bid, citing reasons for the rejection [1]

Group 1 - LENZ Therapeutics, Inc. (NASDAQ: LENZ) has made steady progress towards its first approval since August, when it was previously rated as a BUY [1] - The stock price of LENZ nearly doubled in November but has since decreased significantly [1] Group 2 - Total Pharma Tracker offers tools for DIY investors, including a software that provides extensive curated research material for any ticker [3] - The platform also provides hands-on support from in-house experts who identify the best investable stocks along with buy/sell strategies and alerts [3]

Group 1 - The article discusses the author's long-term investment experience with TG Therapeutics, Inc. (NASDAQ: TGTX), marking the fifth anniversary since the initial purchase of TGTX stock [1] - The Total Pharma Tracker (TPT) service offers tools for DIY investors, including a software that provides extensive curated research material for any ticker [1] - TPT also provides hands-on support from in-house experts who identify the best investable stocks along with buy/sell strategies and alerts [2] Group 2 - The TPT service includes a free trial for potential investors to access tools and evaluate the service without any cost [2]